Is Sanofi (SNY) One of the Best Affordable Blue Chip Stocks to Buy Now?

Sanofi (NASDAQ:SNY) is simply a healthcare biopharmaceutical institution that engages successful the research, development, manufacture, and selling of therapeutic solutions.

On April 13, Citi expert Graham Parry raised the firm’s terms people connected Sanofi (NASDAQ:SNY) from €80 to €82, portion maintaining a ‘Neutral’ standing connected the shares.

Sanofi (NASDAQ:SNY) is targeting income to turn by a precocious single-digit percent successful FY 2026, with concern EPS surging somewhat faster than sales. The institution expects this profitable maturation to proceed for astatine slightest 5 years. Moreover, Sanofi plans to execute a stock buyback programme of €1B this year.

The beardown guidance comes contempt Sanofi (NASDAQ:SNY) undergoing a important enactment alteration this month, with Belén Garijo taking complaint arsenic the company’s caller main enforcement serviceman connected April 29.

With an awesome yearly dividend output of 5.04%, Sanofi (NASDAQ:SNY) was precocious included successful our database of the 15 Large-cap Stocks with Highest Dividends.

While we admit the imaginable of SNY arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Most Undervalued Natural Gas Stocks to Buy Now and 15 Best Blue Chip Stocks to Buy Now

Disclosure: None. Follow Insider Monkey connected Google News.